Abstract
The administration of multiple cytostatic drugs on a weekly basis has been proposed as a new intensive chemotherapy modality for small-cell lung cancer. The European Lung Cancer Working Party has conducted a randomized trial comparing to a standard regimen (cyclophosphamide + adriamycin + etoposide given at the cycle beginning) a weekly chemotherapy with 7 active drugs (cyclophosphamide + adriamycin + etoposide on day 1; cisplatin + vindesine on day 8; methotrexate + vincristine on day 15). A total of 215 eligible patients have been registered. There has been no significant difference between the 2 arms for response and for survival. The total relative dose-intensity has been lower in the weekly chemotherapy arm. This approach has failed to improve current results.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase III
-
Comparative Study
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Small Cell / drug therapy*
-
Carcinoma, Small Cell / mortality
-
Cisplatin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Dose-Response Relationship, Drug
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Prognosis
-
Survival Rate
-
Vincristine / administration & dosage
-
Vindesine / administration & dosage
Substances
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin
-
Vindesine
-
Methotrexate